Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
2(22%)
Results Posted
20%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_3
1
11%
Ph phase_2
4
44%
Ph phase_1
4
44%

Phase Distribution

4

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(5)
Terminated(2)

Detailed Status

Completed5
Active, not recruiting1
Terminated1
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (44.4%)
Phase 24 (44.4%)
Phase 31 (11.1%)

Trials by Status

active_not_recruiting111%
terminated111%
withdrawn111%
completed556%
recruiting111%

Recent Activity

2 active trials
Showing 5 of 9
completedphase_2

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

NCT04232280
recruitingphase_2

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

NCT05683457
completedphase_1

A Study of Modified mRNA Vaccines in Healthy Adults

NCT05397223
completedphase_2

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

NCT04975893
active_not_recruitingphase_1

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

NCT05575492
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04232280Phase 2

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

Completed
NCT05683457Phase 2

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

Recruiting
NCT05397223Phase 1

A Study of Modified mRNA Vaccines in Healthy Adults

Completed
NCT04975893Phase 2

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

Completed
NCT05575492Phase 1

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Active Not Recruiting
NCT05085366Phase 3

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Terminated
NCT06133010Phase 2

A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients

Withdrawn
NCT05105048Phase 1

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

Completed
NCT03382405Phase 1

Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9